Minhai COVID-19 vaccine

Minhai COVID-19 vaccine
Vaccine description
TargetSARS-CoV-2
Vaccine typeInactivated
Clinical data
Other namesKCONVAC (Chinese: 可维克; pinyin: Kěwéikè)
Routes of
administration		Intramuscular
Legal status
Legal status

Minhai COVID-19 vaccine (Chinese: 康泰民海新冠疫苗), trademarked as KCONVAC (Chinese: 可维克; pinyin: Kěwéikè), is a COVID-19 vaccine developed by Shenzhen Kangtai Biological Products Co. Ltd and its subsidiary, Beijing Minhai Biotechnology Co., Ltd.

Clinical trials

In October 2020, KCONVAC started phase I clinical trials with 180 participants in China.[1]

Later, KCONVAC started phase II trials with 1,000 participants in China.[2]

In May 2021, KCONVAC started phase III trials for global trials with 28,000 participants.[3]

Children and adolescents trials

In August 2021, KCONVAC started phase I trials with 84 participants in China.[4]

In September, KCONVAC started phase II trials with 480 participants in China.[5]

Authorizations

On 14 May 2021, the vaccine became the fourth inactivated Chinese Vaccine to be authorised for emergency use.[6]

References

  1. ↑ "A Study to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)". clinicaltrials.gov. United States National Library of Medicine. 16 February 2021. Retrieved 21 March 2021.{{cite journal}}: CS1 maint: url-status (link)
  2. ↑ "A Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)". clinicaltrials.gov. United States National Library of Medicine. 16 February 2021. Retrieved 21 March 2021.{{cite journal}}: CS1 maint: url-status (link)
  3. ↑ "A Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Adults Aged 18 Years and Older (COVID-19)". clinicaltrials.gov. United States National Library of Medicine. 20 April 2021. Retrieved 22 April 2021.{{cite journal}}: CS1 maint: url-status (link)
  4. ↑ "A Phase I Clinical Trial of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Population Aged 3 to 17 Years (COVID-19)". clinicaltrials.gov. United States National Library of Medicine. 12 August 2021. Retrieved 12 August 2021.{{cite journal}}: CS1 maint: url-status (link)
  5. ↑ "A Phase II Clinical Trial of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Population Aged 3 to 17 Years (COVID-19)". clinicaltrials.gov. United States National Library of Medicine. 12 August 2021. Retrieved 12 August 2021.{{cite journal}}: CS1 maint: url-status (link)
  6. ↑ Reuters Staff (14 May 2021). "Kangtai Biological's COVID-19 vaccine gets emergency use approval in China". Reuters. Retrieved 20 May 2021.


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.